AMC is the theatrical distributor for “Taylor Swift: The Eras Tour.”
The Fed: Tighter financial conditions are going to do some of the Fed’s work for it: Waller
Tighter financial conditions are doing some of the Fed’s work, said Fed Gov Christopher Waller on Wednesday.
: Michael Lewis on the outrage over his Sam Bankman-Fried portrayal: ‘It sells the book’
The author Michael Lewis says his book on Sam Bankman-Fried is thriving on the outrage that has been generated.
: Americans are less confident they can make the minimum payments on their credit cards, New York Fed says
Consumers’ expectation of missing a minimum payment is at the highest level since May 2020, according to the Federal Reserve Bank of New York’s latest survey.
The View From Unretirement: In retirement, time is short. Don’t waste it on things you hate.
Saying no to projects and people can be tough. Here’s how to do it.
: ‘Barbie’ in the rear view mirror. Here’s a potential red flag for a U.S. consumer spending slowdown.
Torsten Slok, chief economist at Apollo Global Management, says falling movie theater attendance in recent weeks could be flagging a softer consumer setup.
Market Extra: ‘When money is free, you squander it,’ says former FDIC chair Sheila Bair
Higher interest rates may be painful in the short term, but banks, savers and the financial ecosystem will be better off in the long run, says Sheila Bair, former chair of the Federal Deposit Insurance Corp.
: U.S. corporate bankruptcies accelerate in third quarter as 2023 rivals 2020 as worst year in more than a decade
U.S. bankruptcy filings continued to mount in September, leaving 2023 on track to potentially surpass 2020 as the worst year for corporate bankruptcies in more than a decade.
Economic Report: U.S. producer price inflation comes in a little hotter in September, highest annual rate in five months
U.S. headline producer price inflation rose at a 2.2% annual rate in September, up from 2% in the prior month and the fastest pace since April.
: Amgen’s cancer-drug pipeline looks promising despite FDA setback, analysts say
Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade
- « Previous Page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- …
- 1275
- Next Page »